Welcome to our dedicated page for I-MAB American Depositary Shares news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-MAB American Depositary Shares stock.
I-Mab American Depositary Shares (Nasdaq: IMAB) represent a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel and highly differentiated biologics to treat diseases with unmet medical needs, focusing on cancers and autoimmune disorders. With operations in Rockville, Maryland, and San Diego, California, I-Mab is actively involved in groundbreaking research and innovative drug development.
The company’s pipeline includes several promising candidates:
- Felzartamab (TJ202): A CD38 antibody in Phase III trials for multiple myeloma and autoimmune diseases.
- Eftansomatropin (TJ101): A long-acting human growth hormone that has completed Phase II trials for pediatric growth hormone deficiency.
- Olamkicept (TJ301): An IL-6 blocker in Phase II trials for ulcerative colitis and autoimmune diseases.
- Enoblituzumab: A humanized B7-H3 antibody that has completed Phase I trials for head and neck cancer and other oncology diseases.
- Efineptakin (TJ107): A long-acting recombinant human IL-7 in Phase II trials for glioblastoma multiforme (GBM).
I-Mab's innovative pipeline is driven by its internal R&D strategies, Fast-to-Proof-of-Concept, and Fast-to-Market development, often in collaboration with global partners. Recently, I-Mab announced the divestiture of its Chinese assets and operations, aiming to focus on the U.S. and other international markets. This strategic move included the transfer of its Greater China rights for various assets, potentially generating up to US$80 million based on future milestone achievements.
Notably, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate givastomig combined with nivolumab and chemotherapy as a first-line treatment for advanced Claudin 18.2-positive gastric and esophageal cancers. I-Mab’s robust development pipeline and strategic global partnerships exemplify its commitment to advancing novel therapies to address critical medical needs.
For the latest updates and detailed information, visit the official website at I-Mab Biopharma.
I-Mab (Nasdaq: IMAB) announced that it will present clinical data from a Phase 2 study of lemzoparlimab (TJC4) combined with azacitidine for higher risk myelodysplastic syndrome (HR-MDS) at the ESMO Congress 2022, scheduled from September 9-13, 2022. The abstract, titled Lemzoparlimab in Combination with Azacitidine in Patients with HR-MDS (Abstract #3823), highlights initial clinical results. This study represents a significant step in I-Mab's ongoing research into innovative cancer therapies, following its collaboration with AbbVie for global development.
I-Mab, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker IMAB, is set to host its 2022 Research and Development (R&D) Day on July 20, 2022. The event will feature presentations from key executives including Dr. Jingwu Zang and Dr. Andrew Zhu, focusing on the company's innovative assets and clinical development strategies. The Mandarin session begins at 9:00 am CST, while the English session starts at 8:00 am EST. Interested participants can find registration links for both sessions in the official announcement.
I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, received top rankings in five categories from Institutional Investor in its 2022 All-Asia Executive Team survey. The awards included 'Best CEO' for Dr. Jingwu Zang and 'Best CFO' for John Long, highlighting the company's leadership, corporate governance, and ESG strategy. This marks I-Mab's second consecutive year as the 'Honored Company' in healthcare. The recognition underscores I-Mab's commitment to innovation and value creation, affirming its trajectory as a competitive player in the biopharmaceutical sector.
I-Mab (Nasdaq: IMAB) announced the advancement of two assets through new licensing agreements with MorphoSys AG (FSE: MOR). The agreements grant Human Immunology Biosciences, Inc. exclusive rights to develop and commercialize felzartamab and TJ210 outside Greater China. Felzartamab is in registrational trials for multiple myeloma in China, while TJ210 is undergoing Phase 1 trials in the U.S. These developments enhance I-Mab's position in the biopharmaceutical sector and aim to expedite the availability of innovative therapies to patients.
I-Mab (Nasdaq: IMAB) announced new licensing agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR) for felzartamab (TJ202/MOR202) and TJ210 (MOR210). HIBio will develop and commercialize these antibodies outside Greater China and South Korea. I-Mab retains exclusive rights for felzartamab in Greater China, having made significant progress toward its registration. The agreements aim to advance clinical development and commercialization, with ongoing trials for both products in different regions. These initiatives reflect I-Mab's strategy to expand its innovative drug pipeline globally.
MorphoSys and Human Immunology Biosciences (HIBio) have entered into agreements for HIBio to develop and commercialize the monoclonal antibodies felzartamab and MOR210. MorphoSys will receive a 15% equity stake in HIBio and up to $1 billion in milestone payments, plus royalties. This partnership allows MorphoSys to concentrate on advancing its oncology pipeline, including potential best-in-class treatments. HIBio holds exclusive rights for these antibodies globally, except in specified regions.
Genexine has announced that its partner, I-Mab, completed patient enrollment in a phase 3 clinical trial of eftansomatropin alfa (GX-H9/TJ101) in China. This long-acting growth hormone aims to treat pediatric growth hormone deficiency (PGHD) and is compared to Norditropin® in a study involving 168 patients. This milestone is pivotal for commercialization in a significant market. Final data from the study is expected in 2023, with a potential Biologics License Application to follow. Eftansomatropin alfa could offer advantages over traditional therapies due to its unique formulation.
Ferring Pharmaceuticals has entered a strategic collaboration with I-Mab to further develop olamkicept for inflammatory bowel disease (IBD). Olamkicept is the first clinical-stage selective interleukin-6 (IL-6) inhibitor utilizing a trans-signaling mechanism. Positive Phase 2 study results for olamkicept in ulcerative colitis were presented at the 2021 ECCO meeting. This collaboration offers I-Mab options for future development milestones while Ferring expands olamkicept's global development. Financial terms of the agreement remain undisclosed.
Genexine announced results from the KEYNOTE-899 phase 1b/2 clinical trial of GX-I7 (efineptakin alfa) with pembrolizumab. The trial demonstrated safety and early anti-tumor activity in patients with R/R metastatic TNBC. Overall response rates (ORR) were 15.7% in phase 1b and 21.2% in phase 2, with a notable 60% ORR in PD-L1 positive patients. CEO Neil Warma highlighted the potential of GX-I7 as a first-in-class treatment. Genexine is focusing on global development in multiple cancers with partners NeoImmune Tech and I-Mab.
I-Mab (Nasdaq: IMAB) has completed patient enrollment in the Phase 3 TALLER clinical trial for eftansomatropin alfa (TJ101), targeting pediatric growth hormone deficiency (PGHD) in China. The study enrolled 168 patients and aims to assess the efficacy and safety of the long-acting growth hormone compared to daily alternatives. Final data is expected in 2023, followed by a Biologics License Application submission. The company is collaborating with Jumpcan Pharmaceutical Group to expedite the commercialization of this novel therapy, addressing a significant unmet need in PGHD treatment.
FAQ
What is the current stock price of I-MAB American Depositary Shares (IMAB)?
What is the market cap of I-MAB American Depositary Shares (IMAB)?
What is I-Mab's core focus?
What are some key products in I-Mab's pipeline?
Where are I-Mab's main operations located?
What recent strategic move has I-Mab made?
What is felzartamab?
Who is I-Mab collaborating with on givastomig?
How does I-Mab fund its operations and research?
What is the significance of the FDA's Breakthrough Therapy designation for felzartamab?
What is I-Mab's approach to drug development?
How can investors stay updated on I-Mab's progress?
